Bernardo Dell'osso

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2093453/publications.pdf

Version: 2024-02-01

216 papers 6,415 citations

57758 44 h-index 95266 68 g-index

229 all docs

229 docs citations

times ranked

229

8219 citing authors

#	Article	IF	CITATIONS
1	Epidemiologic and clinical updates on impulse control disorders: a critical review. European Archives of Psychiatry and Clinical Neuroscience, 2006, 256, 464-475.	3.2	201
2	The use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders. Expert Opinion on Drug Metabolism and Toxicology, 2007, 3, 741-753.	3.3	173
3	Selective DNA Methylation of BDNF Promoter in Bipolar Disorder: Differences Among Patients with BDI and BDII. Neuropsychopharmacology, 2012, 37, 1647-1655.	5.4	166
4	Do Benzodiazepines Still Deserve a Major Role in The Treatment of Psychiatric Disorders? A Critical Reappraisal. European Psychiatry, 2013, 28, 7-20.	0.2	164
5	Duration of untreated illness and suicide in bipolar disorder: a naturalistic study. European Archives of Psychiatry and Clinical Neuroscience, 2010, 260, 385-391.	3.2	162
6	The prevalence and burden of bipolar depression. Journal of Affective Disorders, 2014, 169, S3-S11.	4.1	156
7	Dietary Neurotransmitters: A Narrative Review on Current Knowledge. Nutrients, 2018, 10, 591.	4.1	138
8	Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 1-4.	4.8	128
9	Augmentative repetitive navigated transcranial magnetic stimulation (rTMS) in drugâ€resistant bipolar depression. Bipolar Disorders, 2009, 11, 76-81.	1.9	121
10	Biological markers for anxiety disorders, OCD and PTSD – a consensus statement. Part I: Neuroimaging and genetics. World Journal of Biological Psychiatry, 2016, 17, 321-365.	2.6	118
11	What Happened to Patients With Obsessive Compulsive Disorder During the COVID-19 Pandemic? A Multicentre Report From Tertiary Clinics in Northern Italy. Frontiers in Psychiatry, 2020, 11, 720.	2.6	112
12	Is cyberchondria a new transdiagnostic digital compulsive syndrome? A systematic review of the evidence. Comprehensive Psychiatry, 2020, 99, 152167.	3.1	112
13	Age at onset and latency to treatment (duration of untreated illness) in patients with mood and anxiety disorders: a naturalistic study. International Clinical Psychopharmacology, 2010, 25, 172-179.	1.7	108
14	Autosomal Dominant Frontotemporal Lobar Degeneration Due to the C9ORF72 Hexanucleotide Repeat Expansion: Late-Onset Psychotic Clinical Presentation. Biological Psychiatry, 2013, 74, 384-391.	1.3	105
15	Comorbidity in obsessive–compulsive disorder (OCD): A report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). Comprehensive Psychiatry, 2014, 55, 1513-1519.	3.1	105
16	A relationship between oxytocin and anxiety of romantic attachment. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 28.	1.2	99
17	Early intervention for obsessive compulsive disorder: An expert consensus statement. European Neuropsychopharmacology, 2019, 29, 549-565.	0.7	92
18	Validation of the Italian version of the "Mood Disorder Questionnaire" for the screening of bipolar disorders. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 8.	1.2	87

#	Article	IF	CITATIONS
19	Can Long-Term Outcomes Be Improved by Shortening the Duration of Untreated Illness in Psychiatric Disorders? A Conceptual Framework. Psychopathology, 2013, 46, 14-21.	1.5	85
20	Epigenetic modulation of BDNF gene: Differences in DNA methylation between unipolar and bipolar patients. Journal of Affective Disorders, 2014, 166, 330-333.	4.1	85
21	Epigenetic Modulation of BDNF Gene in Patients with Major Depressive Disorder. Biological Psychiatry, 2013, 73, e6-e7.	1.3	79
22	Meta-Review of Metanalytic Studies with Repetitive Transcranial Magnetic Stimulation (rTMS) for the Treatment of Major Depression. Clinical Practice and Epidemiology in Mental Health, 2011, 7, 167-177.	1.2	78
23	The Noradrenergic Action in Antidepressant Treatments: Pharmacological and Clinical Aspects. CNS Neuroscience and Therapeutics, 2011, 17, 723-732.	3.9	74
24	Psychiatric Symptoms in Frontotemporal Dementia: Epidemiology, Phenotypes, and Differential Diagnosis. Biological Psychiatry, 2015, 78, 684-692.	1.3	73
25	Serotonin norepinephrine reuptake inhibitors (SNRIs) in anxiety disorders: a comprehensive review of their clinical efficacy. Human Psychopharmacology, 2010, 25, 17-29.	1.5	70
26	Transcranial direct current stimulation for the outpatient treatment of poor-responder depressed patients. European Psychiatry, 2012, 27, 513-517.	0.2	70
27	Duration of Untreated Illness as a Predictor of Treatment Response and Clinical Course in Generalized Anxiety Disorder. CNS Spectrums, 2008, 13, 415-422.	1.2	68
28	Epigenetic Regulation of Fatty Acid Amide Hydrolase in Alzheimer Disease. PLoS ONE, 2012, 7, e39186.	2.5	64
29	Neurodevelopment and inflammatory patterns in schizophrenia in relation to pathophysiology. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2013, 42, 63-70.	4.8	63
30	Neuropsychobiological Aspects, Comorbidity Patterns and Dimensional Models in Borderline Personality Disorder. Neuropsychobiology, 2010, 61, 169-179.	1.9	56
31	Differences in latency to first pharmacological treatment (duration of untreated illness) in anxiety disorders: a study on patients with panic disorder, generalized anxiety disorder and obsessive–compulsive disorder. Microbial Biotechnology, 2013, 7, 374-380.	1.7	56
32	Characterizing impulsivity profile in patients with obsessive–compulsive disorder. International Journal of Psychiatry in Clinical Practice, 2014, 18, 156-160.	2.4	56
33	May duration of untreated illness influence the long-term course of major depressive disorder?. European Psychiatry, 2008, 23, 92-96.	0.2	55
34	Duration of Untreated Psychosis and Duration of Untreated Illness: New Vistas. CNS Spectrums, 2010, 15, 238-246.	1.2	55
35	Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. Journal of Psychopharmacology, 2014, 28, 596-602.	4.0	55
36	A preliminary study of endocannabinoid system regulation in psychosis: Distinct alterations of CNR1 promoter DNA methylation in patients with schizophrenia. Schizophrenia Research, 2017, 188, 132-140.	2.0	54

#	Article	IF	CITATIONS
37	Topiramate plus paroxetine in treatment-resistant obsessive–compulsive disorder. International Clinical Psychopharmacology, 2006, 21, 189-191.	1.7	53
38	The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). European Neuropsychopharmacology, 2013, 23, 865-871.	0.7	53
39	Clinical predictors of acute response to transcranial direct current stimulation (tDCS) in major depression. Journal of Affective Disorders, 2017, 219, 25-30.	4.1	53
40	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive–compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). International Journal of Psychiatry in Clinical Practice, 2016, 20, 210-217.	2.4	50
41	Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. Journal of Psychopharmacology, 2008, 22, 210-213.	4.0	49
42	The C9ORF72 hexanucleotide repeat expansion is a rare cause of schizophrenia. Neurobiology of Aging, 2014, 35, 1214.e7-1214.e10.	3.1	49
43	Augmentation strategy with olanzapine in resistant obsessive compulsive disorder: an Italian long-term open-label study. Journal of Psychopharmacology, 2005, 19, 392-394.	4.0	48
44	Consequences for the Elderly After COVID-19 Isolation: FEaR (Frail Elderly amid Restrictions). Frontiers in Psychology, 2020, 11, 565052.	2.1	48
45	<p>Healthy Eating, Physical Activity, and Sleep Hygiene (HEPAS) as the Winning Triad for Sustaining Physical and Mental Health in Patients at Risk for or with Neuropsychiatric Disorders: Considerations for Clinical Practice</p> . Neuropsychiatric Disease and Treatment, 2020, Volume 16. 55-70.	2.2	48
46	Bridging the gap between education and appropriate use of benzodiazepines in psychiatric clinical practice. Neuropsychiatric Disease and Treatment, 2015, 11, 1885.	2.2	47
47	Predictors of Clinical Outcome in Schizophrenic Patients Responding to Clozapine. Journal of Clinical Psychopharmacology, 2003, 23, 660-664.	1.4	46
48	A Low FODMAP Gluten-Free Diet Improves Functional Gastrointestinal Disorders and Overall Mental Health of Celiac Disease Patients: A Randomized Controlled Trial. Nutrients, 2018, 10, 1023.	4.1	46
49	Food Bioactive Compounds and Their Interference in Drug Pharmacokinetic/Pharmacodynamic Profiles. Pharmaceutics, 2018, 10, 277.	4.5	45
50	Comorbidity issues in the pharmacological treatment of Pathological Gambling: a critical review. Clinical Practice and Epidemiology in Mental Health, 2005, 1, 21.	1.2	44
51	An epidemiologic and clinical overview of medical and psychopathological comorbidities in major psychoses. European Archives of Psychiatry and Clinical Neuroscience, 2011, 261, 489-508.	3.2	44
52	Altered prefrontal cortex activity during working memory task in Bipolar Disorder: A functional Magnetic Resonance Imaging study in euthymic bipolar I and II patients. Journal of Affective Disorders, 2015, 184, 116-122.	4.1	43
53	Crosstalk between the transcriptional regulation of dopamine D2 and cannabinoid CB1 receptors in schizophrenia: Analyses in patients and in perinatal Δ9-tetrahydrocannabinol-exposed rats. Pharmacological Research, 2021, 164, 105357.	7.1	43
54	Balancing benefits and harms of treatments for acute bipolar depression. Journal of Affective Disorders, 2014, 169, S24-S33.	4.1	41

#	Article	IF	CITATIONS
55	American tertiary clinic-referred bipolar II disorder compared to bipolar I disorder: More severe in multiple ways, but less severe in a few other ways. Journal of Affective Disorders, 2015, 188, 257-262.	4.1	40
56	Treatment of bipolar disorder: Review of evidence regarding quetiapine and lithium. Journal of Affective Disorders, 2016, 191, 256-273.	4.1	40
57	Assessing Working Memory via N-Back Task in Euthymic Bipolar I Disorder Patients: A Review of Functional Magnetic Resonance Imaging Studies. Neuropsychobiology, 2013, 68, 63-70.	1.9	39
58	Mood stabilizers for patients with bipolar disorder: the state of the art. Expert Review of Neurotherapeutics, 2011, 11, 85-99.	2.8	36
59	Augmentative Repetitive Transcranial Magnetic Stimulation (rTMS) in the Acute Treatment of Poor Responder Depressed Patients: A Comparison Study Between High and Low Frequency Stimulation. European Psychiatry, 2015, 30, 271-276.	0.2	36
60	The MCP-1 Gene (SCYA2) and Mood Disorders: Preliminary Results of a Case-Control Association Study. NeuroImmunoModulation, 2010, 17, 126-131.	1.8	35
61	The impact of psychosis on brain anatomy in bipolar disorder: A structural MRI study. Journal of Affective Disorders, 2018, 233, 100-109.	4.1	35
62	Progranulin Gene Variability and Plasma Levels in Bipolar Disorder and Schizophrenia. PLoS ONE, 2012, 7, e32164.	2.5	34
63	<i>C9ORF72</i> hexanucleotide repeat expansion as a rare cause of bipolar disorder. Bipolar Disorders, 2014, 16, 448-449.	1.9	32
64	Duration of untreated illness and depression severity are associated with cognitive impairment in mood disorders. International Journal of Psychiatry in Clinical Practice, 2020, 24, 227-235.	2.4	32
65	Progranulin gene (GRN) promoter methylation is increased in patients with sporadic frontotemporal lobar degeneration. Neurological Sciences, 2013, 34, 899-903.	1.9	30
66	Parsing the phenotype of obsessive-compulsive tic disorder (OCTD): a multidisciplinary consensus. International Journal of Psychiatry in Clinical Practice, 2017, 21, 156-159.	2.4	30
67	Prevalence of suicide attempt and clinical characteristics of suicide attempters with obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2018, 23, 59-66.	1.2	30
68	Impulsive–Compulsive Buying Disorder: Clinical Overview. Australian and New Zealand Journal of Psychiatry, 2008, 42, 259-266.	2.3	29
69	Patterns of Axis I comorbidity in relation to age in patients with Bipolar Disorder: A cross-sectional analysis. Journal of Affective Disorders, 2011, 130, 318-322.	4.1	29
70	Lifetime presence of psychotic symptoms in bipolar disorder is associated with less favorable socio-demographic and certain clinical features. Comprehensive Psychiatry, 2017, 76, 169-176.	3.1	29
71	Coeliac disease and psychiatric comorbidity: epidemiology, pathophysiological mechanisms, quality-of-life, and gluten-free diet effects. International Review of Psychiatry, 2017, 29, 489-503.	2.8	29
72	Exploring the role of BDNF DNA methylation and hydroxymethylation in patients with obsessive compulsive disorder. Journal of Psychiatric Research, 2019, 114, 17-23.	3.1	29

#	Article	IF	CITATIONS
73	Has Bipolar Disorder become a predominantly female gender related condition? Analysis of recently published large sample studies. International Journal of Bipolar Disorders, 2021, 9, 3.	2.2	29
74	Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder. International Clinical Psychopharmacology, 2011, 26, 201-205.	1.7	28
75	Effect of Quetiapine and Norquetiapine on Anxiety and Depression in Major Psychoses Using a Pharmacokinetic Approach. Clinical Drug Investigation, 2012, 32, 213-219.	2.2	26
76	Use of adjunctive stimulants in adult bipolar depression. International Journal of Neuropsychopharmacology, 2013, 16, 55-68.	2.1	26
77	Regulation of gene transcription in bipolar disorders: Role of DNA methylation in the relationship between prodynorphin and brain derived neurotrophic factor. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2018, 82, 314-321.	4.8	26
78	Onset polarity in bipolar disorder: A strong association between first depressive episode and suicide attempts. Journal of Affective Disorders, 2017, 209, 182-187.	4.1	25
79	Long-Term Efficacy After Acute Augmentative Repetitive Transcranial Magnetic Stimulation in Bipolar Depression. Journal of ECT, 2011, 27, 141-144.	0.6	24
80	Pain and psychiatry: a critical analysis and pharmacological review. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 31.	1.2	23
81	Which factors influence onset and latency to treatment in generalized anxiety disorder, panic disorder, and obsessive–compulsive disorder?. International Clinical Psychopharmacology, 2016, 31, 347-352.	1.7	23
82	Age at onset in patients with bipolar I and II disorder: a comparison of large sample studies. Journal of Affective Disorders, 2016, 201, 57-63.	4.1	23
83	The Impact of COVID-19 Pandemic on Searching for Health-Related Information and Cyberchondria on the General Population in Italy. Frontiers in Psychiatry, 2021, 12, 754870.	2.6	23
84	Augmentative transcranial magnetic stimulation (TMS) combined with brain navigation in drug-resistant rapid cycling bipolar depression: A case report of acute and maintenance efficacy. World Journal of Biological Psychiatry, 2009, 10, 673-676.	2.6	22
85	Different characteristics associated with suicide attempts among bipolar I versus bipolar II disorder patients. Journal of Psychiatric Research, 2016, 76, 94-100.	3.1	22
86	Did we learn something positive out of the COVID-19 pandemic? Post-traumatic growth and mental health in the general population. European Psychiatry, 2021, 64, 1-27.	0.2	22
87	Manifesto for a European Anxiety Disorders Research Network. European Neuropsychopharmacology, 2010, 20, 426-432.	0.7	21
88	Benefits and harms of low and high second-generation antipsychotics doses for bipolar depression: A meta-analysis. Journal of Psychiatric Research, 2017, 88, 38-46.	3.1	21
89	Italian Bipolar II vs I patients have better individual functioning, in spite of overall similar illness severity. CNS Spectrums, 2017, 22, 325-332.	1.2	21
90	Obesity and obstetric complications are associated with rapid-cycling in Italian patients with bipolar disorder. Journal of Affective Disorders, 2017, 208, 278-283.	4.1	20

#	Article	IF	Citations
91	Investigating duration of illness and duration of untreated illness in obsessive compulsive disorder reveals patients remain at length pharmacologically untreated. International Journal of Psychiatry in Clinical Practice, 2019, 23, 311-313.	2.4	20
92	Slow vs standard upâ€titration of paroxetine in the treatment of panic disorder: A prospective randomized trial. Psychiatry and Clinical Neurosciences, 2010, 64, 612-619.	1.8	19
93	Progranulin gene variability influences the risk for bipolar I disorder, but not bipolar II disorder. Bipolar Disorders, 2014, 16, 769-772.	1.9	19
94	Psychotic versus non-psychotic bipolar disorder: Socio-demographic and clinical profiles in an Italian nationwide study. Australian and New Zealand Journal of Psychiatry, 2019, 53, 772-781.	2.3	19
95	Peripheral Biomarkers in DSM-5 Anxiety Disorders: An Updated Overview. Brain Sciences, 2020, 10, 564.	2.3	19
96	Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy, 2005, 6, 2727-2740.	1.8	18
97	Alterations of the dopamine transporter in resting lymphocytes of patients with different psychotic disorders. Psychiatry Research, 2010, 175, 54-57.	3.3	18
98	Duration of Untreated Illness and Duration of Illness in Anxiety Disorders: Assessment and Influence on Outcome. Modern Problems of Pharmacopsychiatry, 2013, 29, 111-118.	2.5	18
99	Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2015, 20, 469-473.	1.2	18
100	Efficacy and Safety of Transcranial Direct Current Stimulation in Major Depression. Biological Psychiatry, 2011, 69, e23-e24.	1.3	17
101	Assessing efficacy/effectiveness and safety/tolerability profiles of adjunctive pramipexole in bipolar depression. International Clinical Psychopharmacology, 2013, 28, 297-304.	1.7	17
102	Reduced duration of untreated illness over time in patients with schizophrenia spectrum, mood and anxiety disorders. Psychiatry and Clinical Neurosciences, 2016, 70, 202-210.	1.8	17
103	Vagus Nerve Stimulation in Treatment-Resistant Depression. Journal of ECT, 2013, 29, 41-44.	0.6	16
104	Health literacy and the pharmacological treatment of anxiety disorders: a systematic review. Human Psychopharmacology, 2014, 29, 211-215.	1.5	16
105	Augmentative transcranial direct current stimulation (tDCS) in poor responder depressed patients: a follow-up study. CNS Spectrums, 2014, 19, 347-354.	1.2	16
106	Differences in duration of untreated illness, duration, and severity of illness among clinical phenotypes of obsessive-compulsive disorder. CNS Spectrums, 2015, 20, 474-478.	1.2	16
107	Effects of repetitive transcranial magnetic stimulation on suicidal behavior: A systematic review. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2021, 105, 109981.	4.8	16
108	Assessing the Roles of Stimulants/Stimulant-like Drugs and Dopamine-agonists in the Treatment of Bipolar Depression. Current Psychiatry Reports, 2013, 15, 378.	4.5	15

#	Article	IF	CITATIONS
109	Socio-demographic and clinical characterization of patients with Bipolar Disorder I vs II: a Nationwide Italian Study. European Archives of Psychiatry and Clinical Neuroscience, 2018, 268, 169-177.	3.2	15
110	Differentiating multiple vs single lifetime suicide attempters with bipolar disorders: A retrospective study. Comprehensive Psychiatry, 2018, 80, 214-222.	3.1	15
111	Gender-related differences in patients with bipolar disorder: a nationwide study. CNS Spectrums, 2019, 24, 589-596.	1.2	15
112	Genetic and epigenetic architecture of Obsessive-Compulsive Disorder: In search of possible diagnostic and prognostic biomarkers. Journal of Psychiatric Research, 2021, 137, 554-571.	3.1	15
113	Neuroimaging procedures and related acquisitions in bipolar disorder: state of the art. Rivista Di Psichiatria, 2014, 49, 2-11.	0.6	15
114	Intravenous Augmentative Citalopram Versus Clomipramine in Partial/Nonresponder Depressed Patients. Journal of Clinical Psychopharmacology, 2008, 28, 406-410.	1.4	14
115	Lithium overdosage and related tests. International Journal of Bipolar Disorders, 2016, 4, 1.	2.2	14
116	Quetiapine Augmentation of Selective Serotonin Reuptake Inhibitors in Treatment-Resistant Obsessive-Compulsive Disorder: <i>A Six-Month Follow-Up Case Series</i> . CNS Spectrums, 2006, 11, 879-883.	1.2	13
117	Binding of 3H-WIN-35,428 and 125I-RTI-121 to Human Platelet Membranes. Neurochemical Research, 2006, 31, 361-365.	3.3	13
118	Clinical characteristics and long-term response to mood stabilizers in patients with bipolar disorder and different age at onset. Neuropsychiatric Disease and Treatment, 2009, 5, 399.	2.2	13
119	Tolerability and use in co-administration of pregabalin in affective patients: a 6-month prospective naturalistic study. Expert Opinion on Drug Safety, 2012, 11, 893-899.	2.4	13
120	Factors characterizing access and latency to first pharmacological treatment in Italian patients with schizophrenia, mood, and anxiety spectrum disorders. International Clinical Psychopharmacology, 2015, 30, 29-35.	1.7	13
121	Down-regulation of serotonin and dopamine transporter genes in individual rats expressing a gambling-prone profile: A possible role for epigenetic mechanisms. Neuroscience, 2017, 340, 101-116.	2.3	13
122	Using network analysis to explore cognitive domains in patients with unipolar versus bipolar depression: a prospective naturalistic study. CNS Spectrums, 2020, 25, 380-391.	1.2	13
123	Presence and Characterization of the Dopamine Transporter in Human Resting Lymphocytes. Neurochemical Research, 2008, 33, 1011-1016.	3.3	12
124	Standards of care for obsessive–compulsive disorder centres. International Journal of Psychiatry in Clinical Practice, 2016, 20, 204-208.	2,4	12
125	Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. International Journal of Psychiatry in Clinical Practice, 2017, 21, 131-136.	2.4	12
126	Changes in eating behavior after deep brain stimulation for anorexia nervosa. A caseÂstudy. Eating and Weight Disorders, 2020, 25, 1481-1486.	2.5	12

#	Article	lF	Citations
127	Wake-Promoting Pharmacotherapy for Psychiatric Disorders. Current Psychiatry Reports, 2014, 16, 524.	4.5	11
128	Higher adherence to the Mediterranean diet is associated with reduced tics and obsessive-compulsive symptoms: A series of nine boys with Obsessive-Compulsive Tic Disorder. Nutrition Clinique Et Metabolisme, 2019, 33, 227-230.	0.5	11
129	Polypharmacy as maintenance treatment in bipolar illness: A systematic review. Acta Psychiatrica Scandinavica, 2021, 144, 259-276.	4.5	11
130	Factors associated with lifetime suicide attempts in bipolar disorder: results from an Italian nationwide study. European Archives of Psychiatry and Clinical Neuroscience, 2022, 272, 359-370.	3.2	11
131	American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence. International Journal of Bipolar Disorders, 2017, 5, 2.	2.2	10
132	Lifetime anxiety disorder and current anxiety symptoms associated with hastened depressive recurrence in bipolar disorder. Journal of Affective Disorders, 2017, 219, 165-171.	4.1	10
133	Lifetime bipolar disorder comorbidity and related clinical characteristics in patients with primary obsessive compulsive disorder: a report from the International College of Obsessive–Compulsive Spectrum Disorders (ICOCS). CNS Spectrums, 2020, 25, 419-425.	1.2	10
134	Suicidal ideation and suicidal attempts in patients with obsessive-compulsive tic-related disorder vs obsessive-compulsive disorder: results of a multicenter Italian study. CNS Spectrums, 2021, 26, 354-361.	1.2	10
135	A preliminary investigation of Cyberchondria and its correlates in a clinical sample of patients with obsessive–compulsive disorder, anxiety and depressive disorders attending a tertiary psychiatric clinic. International Journal of Psychiatry in Clinical Practice, 2022, 26, 111-122.	2.4	10
136	Efficacy, tolerability, compliance, and quality of life of patients with mood disorders switched from Quetiapine immediate release to extended release. International Clinical Psychopharmacology, 2012, 27, 1.	1.7	9
137	Duration of untreated illness (DUI) and schizophrenia sub-types: A collaborative study between the universities of Milan and Moscow. International Journal of Social Psychiatry, 2013, 59, 765-770.	3.1	9
138	Superior chronic tolerability of adjunctive modafinil compared to pramipexole in treatment-resistant bipolar disorder. Journal of Affective Disorders, 2013, 150, 130-135.	4.1	9
139	Long-term Effects of Vagus Nerve Stimulation in Treatment-resistant Depression: A 5-year Follow up Case Series. Brain Stimulation, 2015, 8, 1229-1230.	1.6	9
140	Coping with celiac disease: how heavy is the burden for caregivers?. Revista Espanola De Enfermedades Digestivas, 2017, 109, 250-255.	0.3	9
141	Correlates of current rapid-cycling bipolar disorder: Results from the Italian multicentric RENDiBi study. European Psychiatry, 2019, 62, 82-89.	0.2	9
142	Aggressiveness and violence in psychiatric patients: a clinical or social paradigm?. CNS Spectrums, 2019, 24, 564-573.	1.2	9
143	Differential core pharmacotherapy in bipolar I versus bipolar II disorder and European versus American patients not in a syndromal episode. International Clinical Psychopharmacology, 2020, 35, 8-18.	1.7	9
144	Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder. Journal of Psychiatric Research, 2020, 131, 209-214.	3.1	9

#	Article	IF	CITATIONS
145	Regulation of oxytocin receptor gene expression in obsessive–compulsive disorder: a possible role for the microbiota-host epigenetic axis. Clinical Epigenetics, 2022, 14, 47.	4.1	9
146	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. Comprehensive Psychiatry, 2022, 116, 152315.	3.1	9
147	Decreased density of peripheral benzodiazepine receptors in psychiatric patients after a suicide attempt. Life Sciences, 2005, 77, 3268-3275.	4.3	8
148	Italian psychiatrists' perception on cognitive symptoms in major depressive disorder. International Journal of Psychiatry in Clinical Practice, 2016, 20, 2-9.	2.4	8
149	Clinical characterization of Italian suicide attempters with bipolar disorder. CNS Spectrums, 2018, 23, 271-277.	1.2	8
150	Effectiveness, tolerability, and dropout rates of vortioxetine in comorbid depression: A naturalistic study. Human Psychopharmacology, 2020, 35, e2750.	1.5	8
151	Anti-SARS-CoV-2 immunoglobulin profile in patients with celiac disease living in a high incidence area. Digestive and Liver Disease, 2022, 54, 3-9.	0.9	8
152	Cognitive Performance in Euthymic Patients with Bipolar Disorder vs Healthy Controls: A Neuropsychological Investigation. Clinical Practice and Epidemiology in Mental Health, 2017, 13, 71-81.	1.2	8
153	Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: a randomized placebo-controlled study. International Clinical Psychopharmacology, 2008, 23, 198-202.	1.7	7
154	Italian patients with more recent onset of Major Depressive Disorder have a shorter duration of untreated illness. International Journal of Clinical Practice, 2017, 71, e12926.	1.7	7
155	Anxiety disorders anticipate the diagnosis of bipolar disorder in comorbid patients: Findings from an Italian tertiary clinic. Journal of Affective Disorders, 2019, 257, 376-381.	4.1	7
156	Immuno-moodulin: A new anxiogenic factor produced by Annexin-A1 transgenic autoimmune-prone T cells. Brain, Behavior, and Immunity, 2020, 87, 689-702.	4.1	7
157	Prevalence and correlates of current suicide risk in an international sample of OCD adults: A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) network and Obsessive Compulsive and Related Disorders Network (OCRN) of the European College of Neuropsychopharmacology, Journal of Psychiatric Research, 2021, 140, 357-363.	3.1	7
158	Prevalence and disability of comorbid social phobia and obsessive–compulsive disorder in patients with panic disorder and generalized anxiety disorder. International Journal of Psychiatry in Clinical Practice, 2014, 18, 248-254.	2.4	6
159	Does initial use of benzodiazepines delay an adequate pharmacological treatment? A multicentre analysis in patients with psychotic and affective disorders. International Clinical Psychopharmacology, 2018, 33, 140-146.	1.7	6
160	Aripiprazole causing false positive urine amphetamine drug screen in an adult patient with bipolar disorder. Comprehensive Psychiatry, 2019, 94, 152126.	3.1	6
161	Exploring characteristics associated with first benzodiazepine prescription in patients with affective disorders and related diagnoses. Human Psychopharmacology, 2019, 34, e2695.	1.5	6
162	Exploring circannual rhythms and chronotype effect in patients with Obsessive-Compulsive Tic Disorder (OCTD): A pilot study. Journal of Affective Disorders, 2020, 262, 286-292.	4.1	6

#	Article	IF	CITATIONS
163	A 6-month follow-up study on response and relapse rates following an acute trial of repetitive transcranial magnetic stimulation in patients with major depression. CNS Spectrums, 2022, 27, 93-98.	1.2	6
164	Correlation between pharmacokinetics and pharmacogenetics of Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Noradrenaline Reuptake Inhibitors and maternal and neonatal outcomes: Results from a naturalistic study in patients with affective disorders. Human Psychopharmacology, 2021, 36, e2772.	1.5	6
165	Reopening Endoscopy after the COVID-19 Outbreak: Indications from a High Incidence Scenario. Journal of Gastrointestinal and Liver Diseases, 2020, 29, 295-299.	0.9	6
166	Factors influencing lithium versus valproate prescription preference in the maintenance treatment of bipolar patients: a report from the Italian Early Career Psychiatrists (SOPSI-GG). International Journal of Psychiatry in Clinical Practice, 2021, 25, 82-89.	2.4	6
167	Topiramate plus citalopram in the treatment of Compulsive-Impulsive Sexual Behaviors. Clinical Practice and Epidemiology in Mental Health, 2006, 2, 9.	1.2	5
168	The impact of brief depressive episodes on the outcome of bipolar disorder and major depressive disorder: A 1-year prospective study. Journal of Affective Disorders, 2011, 134, 133-137.	4.1	5
169	Access and latency to first antipsychotic treatment in Italian patients with schizophrenia and other schizophrenic spectrum disorders across different epochs. Human Psychopharmacology, 2016, 31, 113-120.	1.5	5
170	Functional interventions as augmentation strategies for obsessive-compulsive disorder (OCD): scoping review and expert survey from the international college of obsessive-compulsive spectrum disorders (ICOCS). International Journal of Psychiatry in Clinical Practice, 2021, , 1-16.	2.4	5
171	Mental health during the first wave of COVID-19 in Canada, the USA, Brazil and Italy. International Journal of Psychiatry in Clinical Practice, 2022, 26, 148-156.	2.4	5
172	Deep Brain Stimulation device removal after scar picking behaviors in a patient with treatment-resistant obsessive compulsive disorder. Brain Stimulation, 2013, 6, 96-98.	1.6	4
173	Antidepressants have complex associations with longitudinal depressive burden in bipolar disorder. Journal of Affective Disorders, 2019, 246, 836-842.	4.1	4
174	Antipsychotic use in Northern Italian inter-episode bipolar disorder patients: considering both second- and first-generation agents. International Clinical Psychopharmacology, 2020, 35, 49-58.	1.7	4
175	A case of treatment-resistant bipolar depression and comorbid OCD treated with deep brain stimulation of the medial forebrain bundle: 5Âyears follow-up results. Journal of Clinical Neuroscience, 2021, 89, 103-105.	1.5	4
176	New Directions in the Use of Brain Stimulation Interventions in Patients with Obsessive-Compulsive Disorder. Current Medicinal Chemistry, 2019, 25, 5712-5721.	2.4	4
177	Duloxetine in Affective Disorders: a Naturalistic Study on Psychiatric and Medical Comorbidity, Use in Association and Tolerability Across Different Age Groups. Clinical Practice and Epidemiology in Mental Health, 2012, 8, 120-125.	1.2	4
178	OXTR Gene DNA Methylation Levels Are Associated with Discounting Behavior with Untrustworthy Proposers. Brain Sciences, 2022, 12, 98.	2.3	4
179	Escitalopram tolerability as mono- versus augmentative therapy in patients with affective disorders: a naturalistic study. Neuropsychiatric Disease and Treatment, 2013, 9, 205.	2.2	3
180	Use of asenapine as add-on therapy in the treatment of bipolar disorder: a comprehensive review and case series. Expert Opinion on Drug Safety, 2014, 13, 1199-1208.	2.4	3

#	Article	IF	CITATIONS
181	Prevalent Burdensome Mental Disorders Remain Untreated for Years: Manifesto for Early Diagnosis and Treatment. Academic Psychiatry, 2015, 39, 231-232.	0.9	3
182	Differential prevalence and demographic and clinical correlates of antidepressant use in American bipolar I versus bipolar II disorder patients. Journal of Affective Disorders, 2018, 234, 74-79.	4.1	3
183	Suicide attempts and clinical correlates in patients with bipolar I vs II disorder. European Psychiatry, 2018, 52, 113-115.	0.2	3
184	Benzodiazepine ingestion as a way to die by suicide and related safety: the case of an elderly patient. Aging Clinical and Experimental Research, 2019, 31, 287-289.	2.9	3
185	Application of a staging model in patients with obsessive–compulsive disorder: cross-sectional and follow-up results. CNS Spectrums, 2022, 27, 218-224.	1.2	3
186	A longitudinal analysis of a work inclusion model for psychiatric patients in the Mental Health Departments of the city of Milan. International Journal of Social Psychiatry, 2022, 68, 1589-1597.	3.1	3
187	Assessing Learning Needs and Career Attitudes of Italian Psychiatry Residents: Results from a National Survey Conducted by the Italian Society of Psychopathology Young Psychiatrists Section (SOPSI-GG). Clinical Practice and Epidemiology in Mental Health, 2019, 15, 21-29.	1.2	3
188	THE IMPACT OF COVID-19 ONTHE PSYCHIATRIC EMERGENCY DEPARTMENTS OF TWO ITALIAN HOSPITALS IN MILAN. Psychiatry Research, 2021, 307, 114303.	3.3	3
189	Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis. Journal of Interferon and Cytokine Research, 2013, 33, 9-14.	1.2	2
190	Italian prescribing patterns in obsessive–compulsive disorder. Human Psychopharmacology, 2017, 32, e2641.	1.5	2
191	Critical aspects in the legal defence of patients with Tourette's Syndrome: An Italian case series. International Journal of Law and Psychiatry, 2018, 61, 1-5.	0.9	2
192	Ten-year outcome of vagus nerve stimulation-implanted patients with treatment-resistant depression: two Italian cases. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 915-918.	2.2	2
193	Psychiatric, behavioral, and cognitive disorders in patients with extracranial cancers. CNS Spectrums, 2018, 23, 388-401.	1.2	2
194	Clinical features and patterns of psychopharmacological prescription in bipolar patients with vs without anxiety disorders at onset. Microbial Biotechnology, 2020, 14, 714-722.	1.7	2
195	Antidepressants in bipolar disorder: Analysis of correlates overall, and in BD-I and BD-II subsamples. Journal of Affective Disorders, 2021, 292, 352-358.	4.1	2
196	Review: antipsychotic augmentation is effective for people with obsessive-convulsive disorder who are receiving, but not responding to, serotonin reuptake inhibitor monotherapy. Evidence-Based Mental Health, 2007, 10, 24-24.	4.5	1
197	Aspetti neurofisiologici e neuropsichiatrici della stimolazione magnetica transcranica. Quaderni Italiani Di Psichiatria, 2010, 29, 122-133.	0.1	1
198	Clinical Observations About The Strange Case of Dr. Jekyll and Mr. Hyde in Relation to Bipolar Disorder. Academic Psychiatry, 2015, 39, 607-608.	0.9	1

#	Article	IF	Citations
199	Gluten-Free Diet Regimens and Psychiatric Symptoms. American Journal of Psychiatry, 2015, 172, 685-686.	7.2	1
200	Prevalence of Selective Serotonin Reuptake Inhibitor–Related Apathy in Patients With Obsessive Compulsive Disorder. Journal of Clinical Psychopharmacology, 2016, 36, 725-726.	1.4	1
201	Commentary on the Risk of Treatment-Emergent Mania With Methylphenidate in Bipolar Disorder. American Journal of Psychiatry, 2017, 174, 803-804.	7.2	1
202	Misdiagnosis of bipolar disorder in patients with brain metastasis affecting frontal lobes. CNS Spectrums, 2019, 24, 231-232.	1.2	1
203	Shared Obsessive-Compulsive Disorder. Journal of Nervous and Mental Disease, 2019, 207, 311-313.	1.0	1
204	Treatment-related transient splenial lesion of the Corpus Callosum in patients with neuropsychiatric disorders: a literature overview with a case report. Expert Opinion on Drug Safety, 2020, 19, 315-325.	2.4	1
205	Space organization and personnel psychological support: unmet needs in the endoscopic assessment during pandemic. Journal of Gastrointestinal and Liver Diseases, 2021, 30, 308-310.	0.9	1
206	Assessing response, remission, and treatment resistance in patients with obsessive–compulsive disorder with and without tic disorders: results from a multicenter study. CNS Spectrums, 2022, 27, 747-753.	1.2	1
207	Latency to selective serotonin reuptake inhibitor vs benzodiazepine treatment in patients with panic disorder: a naturalistic study. CNS Spectrums, 2023, 28, 46-52.	1.2	1
208	A new tool to assess duration of untreated illness: Psychopathological Onset and Latency to Treatment Questionnaire (POLT-Q). Rivista Di Psichiatria, 2018, 53, 290-298.	0.6	1
209	Neurodevelopmental and Neurodegenerative Alterations in the Pathophysiology of Schizophrenia: Focus on Neuro-Immuno-Inflammation. , 2018, , 337-348.		0
210	Do adolescents and young adults accessing the Emergency Room with substance use receive poor therapeutic indications at discharge? An observational retrospective study. International Journal of Clinical Practice, 2021, , e14890.	1.7	0
211	Successful nutrition-based approach in Gilles de la Tourette syndrome heralding drug side effects: A case report and short review. Nutrition Clinique Et Metabolisme, 2021, 35, 231-236.	0.5	0
212	Neurodevelopment Alterations, Neurodegeneration, and Immunoinflammatory Patterns in the Pathophysiology of Schizophrenia., 2014, , 215-225.		0
213	Innovative Approaches to Hallucinations in Psychosis and Affective Disorders: A Focus on Noninvasive Brain Stimulation Interventions., 2018,, 191-208.		0
214	The Use of Transcranial Magnetic Stimulation (TMS) for Obsessive-Compulsive Disorder (OCD). , 2019, , 277-293.		0
215	Psychiatry and psychopathology. , 0, , 147-176.		0
216	The Imitation Game in Children With Tourette Syndrome: A Lack of Impulse Control to Mirror Environmental Stimuli. Motor Control, 2022, 26, 92-96.	0.6	0